Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer

Documenti analoghi

• High Incidence of Oral Dysesthesias on a Trial of Gefitinib, Paclitaxel, and Concurrent External Beam Radiation for Locally Advanced Head and Neck Cancers
  di: Sharp, Hadley, et al.
  Pubblicazione: (2008)
• Molecular and Clinical Responses in a Pilot Study of Gefitinib with Paclitaxel and Radiation in Locally Advanced Head and Neck Cancer
  di: Van Waes, Carter, et al.
  Pubblicazione: (2009)
• Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
  di: Elghouche, Alhasan, et al.
  Pubblicazione: (2016)
• Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
  di: Alhasan Elghouche, et al.
  Pubblicazione: (2016-01-01)
• Commentary on “Weekly Low‐Dose Versus Three‐Weekly High‐Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non‐Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta‐Analysis of Aggregate Data”
  di: Colevas, A. Dimitrios
  Pubblicazione: (2017)